Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations

Trial Profile

Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations

Suspended
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms NICHE
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 03 Jan 2017 Status changed from recruiting to suspended.
    • 17 Aug 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top